Flask High Quality Molecules
Truck Fast Delivery
Award Trusted by Researchers
Follow us: LinkedIn Contact Security
Go to homepage
Cart
Search

Indazole

  • High-purity Indazole
  • Extensive range of Indazole
  • Ideal for drug discovery applications and organic synthesis
  • Fast delivery and expert support
Indazole compounds are essential building blocks in pharmaceutical research. Our carefully curated selection offers diverse structures for SAR studies and lead optimization, ensuring quality and reliability for your projects.

Browse by Subcategory

Scaffolds Custom Synthesis Functional Groups Building Blocks Linkers Complexes & Reagents Search-guide News

Filters

Filters
Availability
Price (EUR)
Medicinal Properties
sLogP Lipophilicity
Molecular Weight (g/mol)
HBD (H-Bond Donors)
HBA (H-Bond Acceptors)
Sort by:
Active filters:
In Stock
Boronic acids, Fluorides, Oxane, Indazole AS143136-G1

(1-(Tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-1H-indazol-4-yl)boronic acid 97%

CAS: 2374153-25-8
Size: 1 g

Formula C13H14BF3N2O3
MW 314.07
MDL MFCD30609549
Price €529.00 per 1G
Drug-likeness properties Drug-likeness: sLogP 1.434 HBD 2 HBA 5
In Stock
Boronic acids, Indazole AS98004-G1

(1-benzyl-1H-Indazol-5-yl)boronic acid 97%

CAS: 1191062-74-4
Size: 1 g

Formula C14H13BN2O2
MW 252.08
MDL MFCD16657159
Price €355.00 per 1G
Drug-likeness properties Drug-likeness: sLogP 0.7644 HBD 2 HBA 4
In Stock
Alcohol, Indazole AS205463-MG250

(1-Benzylindazol-3-yl)methanol 96%

CAS: 131427-21-9
Size: 250 mg

Formula C15H14N2O
MW 238.29
MDL MFCD01631172
Price €334.00 per 250MG
Drug-likeness properties Drug-likeness: sLogP 2.5769 HBD 1 HBA 3
In Stock
Boronic acids, Indazole AS156639-MG100

(1-Boc-indazol-3-yl)boronic Acid 95%

CAS: 1315339-92-4
Size: 100 mg

Formula C12H15BN2O4
MW 262.07
MDL MFCD07368043
Price €465.00 per 100MG
Drug-likeness properties Drug-likeness: sLogP 0.4993 HBD 2 HBA 6
In Stock
Boronic acids, Indazole AS200961-G1

(1-Butylindazol-5-yl)boronic Acid 96%

CAS: 2377607-59-3
Size: 1 g

Formula C11H15BN2O2
MW 218.06
MDL MFCD27935598
Price €546.00 per 1G
Drug-likeness properties Drug-likeness: sLogP 0.5162 HBD 2 HBA 4
In Stock
Boronic acids, Indazole AS111030-G1

(1-Ethyl-1H-indazol-5-yl)boronic acid 95%

CAS: 952319-70-9
Size: 1 g

Formula C9H11BN2O2
MW 190.01
MDL MFCD22576144
Price €164.00 per 1G
Drug-likeness properties Drug-likeness: sLogP -0.264 HBD 2 HBA 4
In Stock
Boronic acids, Indazole AS200974-G1

(1-Isopropylindazol-5-yl)boronic Acid 98%

CAS: 1551416-99-9
Size: 1 g

Formula C10H13BN2O2
MW 204.04
MDL MFCD27935618
Price €492.00 per 1G
Drug-likeness properties Drug-likeness: sLogP 0.297 HBD 2 HBA 4
In Stock
Alcohol, Indazole AS36608-G1

(1-Methyl-1H-indazol-3-yl)methanol 97%

CAS: 1578-96-7
Size: 1 g

Formula C9H10N2O
MW 162.19
MDL MFCD08060470
Price €150.00 per 1G
Drug-likeness properties Drug-likeness: sLogP 1.0656 HBD 1 HBA 3
In Stock
Amines, Indazole AS141506-G1

(1-Methyl-1H-indazol-5-yl)methanamine 95%

CAS: 267413-27-4
Size: 1 g

Formula C9H11N3
MW 161.20
MDL MFCD12028599
Price €182.00 per 1G
Drug-likeness properties Drug-likeness: sLogP 1.032 HBD 1 HBA 3
In Stock
Amines, Indazole AS59063-B-G1

(1-Methyl-1H-indazol-7-yl)methanamine HCl 95%

CAS: 1810069-86-3
Size: 1 g

Formula C9H12ClN3
MW 197.66
MDL MFCD28502008
Price €444.00 per 1G
Drug-likeness properties Drug-likeness: sLogP 1.4538 HBD 1 HBA 3
In Stock
Alcohol, Indazole AS59207-MG250

(1-Methyl-1H-indazol-7-yl)methanol 97%

CAS: 1092961-08-4
Size: 250 mg

Formula C9H10N2O
MW 162.19
MDL MFCD11052636
Price €146.00 per 250MG
Drug-likeness properties Drug-likeness: sLogP 1.0656 HBD 1 HBA 3
In Stock
Amines, Indazole AS150332-MG250

(1-Methylindazol-6-yl)methanamine 97%

CAS: 267413-31-0
Size: 250 mg

Formula C9H11N3
MW 161.20
MDL MFCD12028600
Price €220.00 per 250MG
Drug-likeness properties Drug-likeness: sLogP 1.032 HBD 1 HBA 3
In Stock
Amines, Indazole AS59063-C-MG250

(1-Methylindazol-7-yl)methanamine diHCl 97%

CAS: -
Size: 250 mg

Formula C9H13Cl2N3
MW 234.12
MDL MFCD34184329
Price €200.00 per 250MG
Drug-likeness properties Drug-likeness: sLogP 1.8756 HBD 1 HBA 3
In Stock
Boronic acids, Oxane, Indazole AS156638-G1

(1-Tetrahydropyran-2-ylindazol-6-yl)boronic Acid 95%

CAS: 2096337-20-9
Size: 1 g

Formula C12H15BN2O3
MW 246.07
MDL MFCD22376757
Price €213.00 per 1G
Drug-likeness properties Drug-likeness: sLogP 0.4152 HBD 2 HBA 5
Boronic acids, Indazole AS184297-MG250

(1,3-Dimethyl-1H-indazol-6-yl)boronic Acid Pinacol Ester 96%

CAS: 1300582-61-9
Size: 250 mg

Formula C15H21BN2O2
MW 272.15
MDL MFCD22566219
Price €336.00 per 250MG
Drug-likeness properties Drug-likeness: sLogP 2.18092 HBD 0 HBA 4
In Stock
Boronic acids, Indazole AS154312-MG100

(1,3-dimethyl-1H-indazol-7-yl)boronic acid 95%

CAS: 1309982-19-1
Size: 100 mg

Formula C9H11BN2O2
MW 190.01
MDL MFCD12028660
Price €358.00 per 100MG
Drug-likeness properties Drug-likeness: sLogP -0.43848 HBD 2 HBA 4
In Stock
Boronic acids, Indazole AS184337-G1

(1,4-Dimethyl-1H-indazol-5-yl)boronic Acid Pinacol Ester 95%

CAS: 2828439-37-6
Size: 1 g

Formula C15H21BN2O2
MW 272.15
MDL MFCD34601912
Price €147.00 per 1G
Drug-likeness properties Drug-likeness: sLogP 2.18092 HBD 0 HBA 4
In Stock
Boronic acids, Indazole AS156925-MG100

(1,6-Dimethyl-1H-indazol-4-yl)boronic Acid 95%

CAS: 1310405-32-3
Size: 100 mg

Formula C9H11BN2O2
MW 190.01
MDL MFCD12028652
Price €331.00 per 100MG
Drug-likeness properties Drug-likeness: sLogP -0.43848 HBD 2 HBA 4
In Stock
Amines, Indazole AS122192-MG250

(1H-Indazol-3-yl)-methyl-amine 97%

CAS: 1006-28-6
Size: 250 mg

Formula C8H9N3
MW 147.18
MDL MFCD10000455
Price €709.00 per 250MG
Drug-likeness properties Drug-likeness: sLogP 1.6046 HBD 2 HBA 2
In Stock
Amines, Indazole AS22259-G1

(1H-Indazol-3-yl)methylamine HCl 95%

CAS: 117891-16-4
Size: 1 g

Formula C8H10ClN3
MW 183.64
MDL MFCD06739150
Price €222.00 per 1G
Drug-likeness properties Drug-likeness: sLogP 1.4434 HBD 2 HBA 2
Indazole AS122220-MG250

(1H-Indazol-5-yl)-hydrazine hydrochloride 96%

CAS: 1012879-50-3
Size: 250 mg

Formula C7H9ClN4
MW 184.63
MDL MFCD22417348
Price €725.00 per 250MG
Drug-likeness properties Drug-likeness: sLogP 1.2703 HBD 3 HBA 3
In Stock
Amines, Indazole AS122163-MG250

(1H-Indazol-5-yl)-methyl-amine 96%

CAS: 478827-05-3
Size: 250 mg

Formula C8H9N3
MW 147.18
MDL MFCD11506089
Price €378.00 per 250MG
Drug-likeness properties Drug-likeness: sLogP 1.6046 HBD 2 HBA 2
In Stock
Amines, Indazole AS41908-MG250

(1H-Indazol-5-yl)methanamine HCl 95%

CAS: 943845-78-1
Size: 250 mg

Formula C8H10ClN3
MW 183.64
MDL MFCD23135684
Price €204.00 per 250MG
Drug-likeness properties Drug-likeness: sLogP 1.4434 HBD 2 HBA 2
Amines, Indazole AS122162-MG250

(1H-Indazol-6-yl)-methyl-amine 98%

CAS: 1086392-14-4
Size: 250 mg

Formula C8H9N3
MW 147.18
MDL MFCD11506088
Price €725.00 per 250MG
Drug-likeness properties Drug-likeness: sLogP 1.6046 HBD 2 HBA 2

Understanding Indazole in Modern Chemistry

Explore the critical role of Indazole in pharmaceutical development, medicinal chemistry research and organic chemistry.

Precision Chemistry

Precision Chemistry

Advanced synthesis techniques for superior quality compounds

Great Molecules for Chemical Diversity

Our catalogue of building blocks contains a diverse range of highly functionalised and decorated compounds. The 20 years of experience in supplying cutting-edge building blocks have given us the expertise to bring you the most exciting chemical motifs, adding chemical diversity to your projects.

Our diverse catalogue is tailored for medicinal chemistry, small molecule drug discovery and organic synthesis. Our unique range of Indazole adds value to any research project.

We constantly add to our catalogue; the latest additions include a range of new Indazole. We continue to bring you the latest and most exciting chemical compounds.

Quality Assurance

Quality Assurance

Every Indazole product in our portfolio undergoes rigorous quality control testing. Our building blocks are supplied with the highest purity standards. We provide complete analytical characterisation, including:

  • ¹H and ¹³C NMR spectroscopy for structural verification
  • HPLC chromatograms confirming purity levels
  • Certificate of Analysis available.
  • Standard purity of 95%
  • Specific purity available upon request.

Diverse Applications

Diverse Applications

From oncology to neuroscience, enabling next-generation therapeutics

Over 1900 Indazole in our catalogue
Found in over 9 FDA-approved drugs
95% of compounds available from stock

Indazole products in our portfolio

Indazole ranks among the most productive scaffolds in contemporary drug discovery. The ring system offers a well-defined planar framework with two nitrogen atoms of differing character, one of which can act as a hydrogen bond donor and the other as a hydrogen bond acceptor, enabling productive interactions with a broad range of biological targets including kinases, nuclear receptors, and ion channels. Indazole derivatives also benefit from generally favourable physicochemical properties including moderate lipophilicity and good aqueous solubility, making them useful starting points for lead optimisation. The C-3 and N-1 positions offer well-established routes for functionalisation, allowing medicinal chemists to tune potency, selectivity, and pharmacokinetic behaviour with considerable flexibility.   

The Indazole scaffold is utilised across multiple therapeutic areas, with particularly strong representation in oncology, where its ability to occupy ATP-binding pockets in kinase active sites has been systematically exploited. Pazopanib (Votrient, GlaxoSmithKline) is an FDA-approved oral multitargeted tyrosine kinase inhibitor built around a dimethylindazolylpyrimidine core, approved for the treatment of advanced renal cell carcinoma through selective inhibition of VEGFR1-3, PDGFR, and c-Kit. Niraparib (Zejula, Tesaro/GSK) is an FDA-approved oral PARP1/2 inhibitor containing an indazole pharmacophore, approved for the maintenance treatment of recurrent platinum-sensitive epithelial ovarian, fallopian tube, and primary peritoneal cancers, and notable as the first PARP inhibitor approved for maintenance therapy regardless of BRCA mutation status.  

Our range of Indazoles features novel substitutions and the incorporation of synthetically tractable functional groups such as boronic acids and esters, amines, carboxylic acids, ketones, hydroxyls and halogens to enable expedient synthetic strategies. Please examine a selection of the Indazole in our catalogue. The full range can be found using the substructure feature of our Search tools.

Explore Our Complete Portfolio

Frequently Asked Questions

Common questions about our Indazole products.

Indazole is a bicyclic ring system consisting of a benzene ring fused to a pyrazole, and it ranks among the most productive scaffolds in contemporary drug discovery. The ring offers two nitrogen atoms of differing character, enabling it to act simultaneously as a hydrogen bond donor and acceptor. This versatility, combined with moderate lipophilicity and good aqueous solubility, makes indazole a useful starting point for lead optimisation across a range of target classes.

The two nitrogen atoms in the indazole ring have different electronic characters, with one capable of donating a hydrogen bond and the other able to accept one. This combination allows indazole-containing compounds to form productive interactions with kinases, nuclear receptors, and ion channels. The planar aromatic framework also supports pi-stacking and hydrophobic contacts within protein binding pockets.
Indazole has particularly strong representation in oncology, where its ability to occupy ATP-binding pockets in kinase active sites has been systematically exploited. Beyond oncology, indazole-containing compounds have been developed across other therapeutic areas as well. The scaffold's physicochemical properties, including moderate lipophilicity and good solubility, support its use in programmes that require oral bioavailability.
Two notable FDA-approved oncology drugs contain indazole pharmacophores. Pazopanib (Votrient, GlaxoSmithKline) is an oral multitargeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma, built around a dimethylindazolylpyrimidine core that inhibits VEGFR1-3, PDGFR, and c-Kit. Niraparib (Zejula, Tesaro/GSK) is an oral PARP1/2 inhibitor approved for platinum-sensitive ovarian cancers and was the first PARP inhibitor approved for maintenance therapy regardless of BRCA mutation status.
The C-3 and N-1 positions of the indazole ring offer well-established routes for functionalisation. Modifications at these positions allow medicinal chemists to tune potency, selectivity, and pharmacokinetic behaviour with considerable flexibility. The availability of diverse functional groups on commercial indazole building blocks, including amines, carboxylic acids, boronic acids, and halogens, supports broad analogue synthesis.
Pazopanib is built around a dimethylindazolylpyrimidine core in which the indazole pharmacophore contributes to selective inhibition of VEGFR1-3, PDGFR, and c-Kit. The planar indazole ring engages the ATP-binding pockets of these kinase targets through hydrogen bonding and hydrophobic burial. This multi-kinase inhibition profile underlies its clinical activity in advanced renal cell carcinoma.
Antwort hier eingeben...

Still have questions?

Our technical support team is here to help with any inquiries about our Indazole products.

Contact Technical Support Request a Quote
This website uses cookies to ensure the best experience possible. More information...